AprilBio announces paid-in capital increase
에이프릴바이오
397030
Signal Score
Historical Avg Return (5d)
+0.33%
Data Coverage
100%n=2377
Risk-adjusted indicator based on 2377 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Initial Conversion Price: 42,953 KRW per share
- • Minimum Preferred Dividend Rate: 1% of par value per share annually
- • Conversion Price Adjustment Floor: 70% of initial conversion price
AI Analysis Summary
AprilBio Co.,Ltd. has announced a decision on a paid-in capital increase. The new shares will be preferred shares with an initial conversion price of 42,953 KRW per share. These preferred shares offer a minimum annual dividend of 1% of their par value and are cumulative and participating. The conversion price can be adjusted downwards, but not below 70% of the initial conversion price. This capital increase could lead to dilution for existing common shareholders upon conversion of the preferred shares. The purpose of the funds and the number of shares to be issued are not specified in the provided content, limiting a full assessment of the dilution impact.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.